Background Treatment of segmental bone loss remains a major challenge in orthopaedic surgery. Traditional techniques (eg, autograft) and newer techniques (eg, recombinant human bone morphogenetic protein-2 [rhBMP-2]) have well-established performance limitations and safety concerns respectively. Consequently there is an unmet need for osteoinductive bone graft substitutes that may eliminate or reduce the use of rhBMP-2. Questions/purposes Using an established rabbit radius osteotomy defect model with positive (autogenous bone graft) and negative (empty sham) control groups, we asked:
Results Six weeks after implantation the collagen-glycosaminoglycan group had callus occupying greater than 1 . 2 the defect, whereas the sham (empty) control defect was still empty and the autogenous bone graft defect was completely filled with unremodeled bone. At 6 weeks, the collagen-hydroxyapatite scaffold groups showed greater defect filling with dense callus compared with the collagenglycosaminoglycan controls. At 16 weeks, the autogenous bone graft groups showed evidence of early-stage medullary canal formation beginning at the proximal and distal defect borders. The collagen-glycosaminoglycan and collagen-glycosaminoglycan-rhBMP-2 groups had nearly complete medullary canal formation and anatomic healing at 16 weeks. However, collagen-hydroxyapatite-rhBMP-2 scaffolds showed the best levels of healing, exhibiting a dense callus which completely filled the defect. Conclusions The collagen-hydroxyapatite scaffold showed comparable healing to the current gold standard of autogenous bone graft. It also performed comparably to collagen-glycosaminoglycan-rhBMP-2, a representative commercial device in current clinical use, but without the cost and safety concerns. Clinical Relevance The collagen-glycosaminoglycan scaffold may be suitable for a low load-bearing defect. The collagen-hydroxyapatite scaffold may be suitable for a load-bearing defect. The rhBMP-2 containing collagenglycosaminoglycan and collagen-hydroxyapatite scaffolds may be suitable for established nonunion defects.
Introduction
Every year, more than two million bone replacement procedures are performed worldwide, which require the use of bone-graft materials, making bone second only to blood on the list of transplanted materials [16] . With demand escalating and increasing limitations with traditional bone graft supply, techniques are being developed to provide alternatives with properties suitable for clinical use [14, 16] . Numerous materials have been used as tissue graft substitutes in the human clinical setting since Yannas and Burke [41] developed the collagen-glycosaminoglycan scaffold for skin grafting. However, poor performance of these compared with the clinical gold standard of autogenous bone grafting has led to an enduring and unmet need for a bioactive, load-bearing, tissue-engineering scaffold, which is biocompatible, biodegradable, and capable of facilitating and promoting osteogenesis in vivo [2, 25, 39] .
Growth factor use for bone repair has increased dramatically since Urist's pioneering work in the 1960s [35] . BMP-2 is part of the transforming growth factor-b superfamily and has an endogenous concentration of approximately 2 lg/kg human bone [30] . Recombinant human bone morphogenetic protein-2 (rhBMP-2) [6] and rhBMP-7 (commercially known as OP-1) [8] have received FDA approval for specified surgical procedures, but initially successful results [29, 44] and subsequent human trials [3, 20] have been questioned in numerous studies citing safety concerns [10, 31, 36, 40] as a result of extensive off-label use. The supraphysiologic rhBMP-2 doses currently used clinically (1.5 mg/cc) are clearly a problem and with as much as 85% off-label use reported [5, 26] , the US Department of Health and Human Services has called for review of current evidence on the safety of rhBMP-2 doses and applications [26] .
Research from our laboratory has led to the development of a highly porous and biocompatible collagen-glycosaminoglycan scaffold optimized in terms of composition [33] , crosslinking density [12] , and pore architecture [21, 23] for use in bone tissue engineering [19] . More recently a biomimetic and highly porous ([ 95%) collagen-hydroxyapatite composite scaffold was developed [11] . By incorporating a ceramic hydroxyapatite particle phase into the optimized collagen-based scaffolds using a patented mixing process [24] , osteoinductive potential in vitro was shown [4] , without using rhBMP-2, while still maintaining high levels of porosity and pore interconnectivity ( Fig. 1 ), prerequisites for cellular interaction and de novo tissue integration with the existing host tissue. In addition, the collagen-hydroxyapatite scaffold is an ideal carrier for low-dose rhBMP-2 retention owing to its mineral component [1, 28, 45] .
Using an established rabbit radius osteotomy defect model with positive (autogenous bone graft) and negative (empty sham) control groups, we asked (1) whether the collagen-glycosaminoglycan alone can heal the defect, (2) whether the addition of hydroxyapatite particles to the collagen scaffold promote faster healing, and (3) by carrying a low-dose rhBMP-2, whether the collagen-glycosaminoglycan and collagenhydroxyapatite scaffolds are able to promote faster healing.
Materials and Methods

Scaffold Fabrication
The collagen-glycosaminoglycan scaffolds were fabricated using a previously described freeze-drying technique [22, 33] by homogenizing Type I collagen (Integra Lifesciences Inc, Plainsboro, NJ, USA) and chondroitin-6-sulfate (Sigma-Aldrich, St Louis, MO, USA) in aqueous acetic acid solution (0.05 mol/L). Collagen-hydroxyapatite scaffolds were synthesized using a previously described freeze-drying technique [11] by forming a suspension of Type I collagen (Integra Lifesciences Inc, Plainsboro, NJ, USA) and hydroxyapatite particles (Plasma Biotal, Tideswell, UK) in 0.5 mol/L aqueous acetic acid using a patented technique [24] .
BMP-loaded Scaffolds
Recombinant human BMP-2 (R&D Systems, Abingdon, UK) was loaded directly onto the scaffolds. Twenty-five micrograms of rhBMP-2 in 25lL solution were pipetted on one side and left for 15 minutes and repeated for the other side before implantation into the defect (50 lg per scaffold). Scaffolds 15 x 5 x 5 mm were used and all were loaded with a final rhBMP-2 concentration of 40 ng/mm 3 .
In Vivo Study
A total of 24, 4-month-old female, New Zealand White rabbits with a mean weight of 3.8 kg were divided into six groups (Table 1) . Four animals were assigned to each investigational group. A power analysis was performed and it was shown that our available sample size would detect a significant change in normalized bone volume mean for each group of 5% (with a CI of 95%) based on a preliminary analysis of the control groups.
Surgical Procedure
Following established techniques [13] , surgery was performed under government license and institution ethical approval. After induction of anesthesia, a 5-cm skin incision was made over the radial aspect of the limb exposing the muscles, which were retracted uninjured. Once exposed, the periosteum was incised and reflected and a Hohmann retractor was placed between the radius and ulna to protect the ulna. Under copious sterile saline irrigation and using a circular saw (Dentalfarm, Torino, Italy), a 15mm transosseous osteotomy was made starting 20 mm from the distal end of the radius extending 15 mm proximally. The defect was either implanted with one of the scaffolds (Fig. 2 ) from Groups 1 through 4, with autogenous bone graft (positive control), or left empty (negative control) and subsequently sutured closed. Autogenous bone graft was prepared by grinding the full excised piece of corticocancellous bone using a pestle and mortar and replacing it in the defect in full in morselized form. Muscles and fascia were sutured closed in layers with 4-0 absorbable suture (Ethicon, Bridgewater, NJ, USA) and the skin was closed with skin clips. Animals were euthanized 16 weeks after surgery with a lethal injection of intravenous phenobarbitone.
Radiographic Imaging
A lateral and AP digital radiograph were taken of both forelimbs of each rabbit (Axiom Aristos FX Plus; Siemens Medical, Munich, Germany) and analyzed (eFilm Workstation 1 Version 3.1 software; Merge Healthcare, Chicago, IL, USA) at 0 (postoperative check radiograph), 6, 12, and 16 weeks postoperatively. A densitometer was used for each image and a value from 0 to 8 was assigned along a healing scale for each specimen by a veterinary radiologist (HMcA) and an orthopaedic surgeon (FGL) blindly and independently. As there is no established scoring system for radiographic bone healing, a simple system was devised by the contributors (FGL and HMcA) to standardize radiograph interpretation; this involved defining distinct stages corresponding to significant iterations in the healing cascade of a segmental defect and assigning values ( Table 2 ). In addition, a fullbody AP and a lateral plain radiograph were taken of each rabbit at 16 weeks to screen for ectopic ossification.
Micro-CT Imaging
Micro-CT (lCT) was used to provide three-dimensional (3-D) information of the excised bones. A Scanco Medical 40
Micro CT system (Bassersdorf, Switzerland) was used and 3-D reconstructions were created at a resolution of 12 lm for all scans. Three-dimensional reconstructions were performed using a threshold of 140 (defect imaging) and a threshold of 180 (quantitative assessment) from a range between 0 and 1000. Quantitative assessment of new cortical bone formation in the defect involved selecting regions of interest (ROIs) in the 3-D reconstructions, located using radiographic data, corresponding with the 15mm long surgically created defect. To ensure only newly mineralized tissue was analyzed, a 10-mm ROI, centrally located in the 15-mm defect, was isolated. Proprietary lCT software (Scanco Medical) was used to define tissue volumes and bone volumes (threshold = 180) in all samples and the ratio of new cortical bone volume to tissue volume (BV/TV) was determined for each group. Histologic Preparation and Histomorphometric Analysis
After lCT analysis, each specimen was bisected sagittally, decalcified in 10% formic acid for 2 weeks, and embedded in paraffin wax. Five-micron thick coronal sections were prepared and stained with hematoxylin and eosin using a routine protocol before examination [19] . Images from each specimen were acquired and digitized using optical and confocal microscopic visualization (Nikon Microscope Eclipse 90i with Nis Elements software Version 3.06; Nikon Instruments, Amsterdam, The Netherlands). Areas in each image were identified (FGL, JPG) as existing cortical bone, new cortical bone, medullary canal, or fibrous tissue. Quantitative histologic analysis was done for each specimen by two observers independently and blindly (FGL, JPG), and a mean value was used to calculate the percentage of new cortical bone volume in the defect. Areas of new bone were identified qualitatively and by using proprietary software (Nis Elements software Version 3.06; Nikon Instruments), the relative area of the tissue subtype was calculated.
Statistical Analysis
Quantitative results are expressed as mean ± SDs. Statistical analysis was performed with SigmaStat 3.0 (SPSS, Chicago, IL, USA) using a general linear model ANOVA with the Holm-Sidak post hoc multiple comparison test. Using this approach, we investigated each of the three research questions: (1) collagen-glycosaminoglycan scaffolds were compared with empty and autogenous bone graft groups to assess their ability to heal the defect; (2) collagenhydroxyapatite scaffolds were compared with collagenglycosaminoglycan scaffolds to compare relative levels of healing; and (3) collagen-glycosaminoglycan-rhBMP-2 and collagen-hydroxyapatite-rhBMP-2 scaffolds were compared with all other groups in terms of levels of healing. Significant differences in mean level of new cortical bone volume in each of the defects were assessed at Week 16. Statistical significance was determined at p \ 0.05.
Results
Implanted collagen-glycosaminoglycan scaffolds alone did not completely heal the defects by 16 weeks. Interpretation of plain radiographs (Fig. 3 ) of the collagen-glycosaminoglycan scaffolds alone indicated bicortical healing but no medullary cavity, even at 16 weeks. This was similar to radiographs of the autogenous bone. However, blinded review of temporal progression of radiographs through the radiographic healing score (Fig. 4) suggested that temporal healing in the collagen-glycosaminoglycan group was slower than in the autogenous bone graft group. Micro-CT images (Fig. 5) show that the collagen-glycosaminoglycan scaffolds resulted in only partial defect bridging and defect filling with bone. Histologically, collagen-glycosaminoglycan-filled defects did show areas of woven bone visible at the center of the defect (Fig. 6 ). Blinded histomorphometric analysis showed that the quantity of new cortical bone was significantly less in the collagen-glycosaminoglycan groups compared with autogenous bone graft; specifically collagen-glycosaminoglycan scaffolds resulted in mean new cortical bone volumes of 19% ± 1.8% compared with autogenous bone graft values of 29% ± 2.2 (p \ 0.001) (Fig. 7) . The BV/TV ratio showed equivalance between the collagen-glycosaminoglycan and autogenous bone graft groups (Fig. 8 ).
The addition of microhydroxyapaptite particles to the collagen scaffold resulted in improved radiologic and histologic healing compared with the collagen-glycosaminoglycan scaffold (p \ 0.001) and equivalent radiologic and histologic healing to autogenous bone graft. Relative to the collagenglycosaminoglycan scaffold alone group, plain radiographs ( Fig. 3) of the collagen-hydroxyapatite scaffold group showed anatomic alignment reflecting native form, and improved healing with evidence of early incomplete marrow cavity formation throughout the length of the defect. Micro-CT images (Fig. 5 ) qualitatively showed the increased volume of healing bone in the collagen-hydroxyapatite group defect relative to the collagen-glycosaminoglycan group. Histologic images (Fig. 6) confirmed the relative increased bone formation, and quantitative histomorphometric analysis (Fig. 7 ) indicated a significant increase in new bone volume compared with collagen-glycosaminoglycan groups (p \ 0.001). Interestingly, lCT analysis showed that the collagenhydroxyapatite group exhibited a significantly increased BV/ TV compared with all other groups (Fig. 8 ).
The addition of rhBMP-2 to the collagen-glycosaminoglycan and collagen-hydroxyapatite scaffolds improved healing relative to the rhBMP-2-free groups. Radiologic and histologic healing was complete by 16 weeks in the collagen-hydroxyapatite-rhBMP-2 group. Plain radiographs and lCT showed anatomically complete healing and this was confirmed histologically with the collagenhydroxyapatite-rhBMP-2 group. Histomorphometric bone volume was 34% ± 3.4%, signifcantly higher than all other groups. The addition of rhBMP-2 to the collagenglycosaminoglycan scaffold also increased healing relative to the collagen-glycosaminoglycan scaffold alone. Collagen-glycosaminoglycan-rhBMP-2 healing was radiologically and histologicially equivalent to the collagen-hydroxyapatite scaffold alone and the autogenous bone graft groups.
Discussion
The results of our study support that collagen-glycosaminoglycan and collagen-hydroxyapatite scaffolds have potential as bone graft substitutes. Using an established animal osteotomy model, we examined radiologic and histologic evidence of healing of (1) the collagen-glycosaminoglycan scaffold; (2) a modification of the collagenglycosaminoglycan scaffold with microhydroxyapatite particles added during fabrication (collagen-hydroxyapatite scaffold); and (3) the collagen-glycosaminoglycan and collagen-hydroxyapatite scaffolds soaked with a low-dose rhBMP-2. Control groups were autogenous bone graft and a sham (empty) control. Each analysis method (plain radiograph, lCT, and histology) showed that the defect did not heal without intervention, showing that the defect was critically sized. Therefore, the healing observed in the remaining groups was the result of the presence of the scaffolds, rhBMP-2, or autogenous bone graft. Collagenglycosaminoglycan scaffolds alone were insufficient to result in healing in 16 weeks. The addition of rhBMP-2 to the collagen-glycosaminoglycan scaffold increased healing relative to the collagen-glycosaminoglycan scaffold alone. Collagen-glycosaminoglycan-rhBMP-2 healing was radiologically and histologicially equivalent to the collagenhydroxyapatite scaffold and autogenous bone graft groups. However, collagen-hydroxyapatite-rhBMP-2 exhibited physiologically complete healing by 16 weeks.
This study has some limitations. First, the study scope does not include evaluation of the Infuse 1 carrier (Medtronic SD, Memphis, TN, USA), Mastergraft 1 (Medtronic SD). Mastergraft 1 has been widely available for numerous years and evaluated extensively [32, 38] . However, the focus of our study was predominantly on the rhBMP-2 and delivery using generic scaffolds not specifically optimized for rhBMP-2. Consequently, we cannot draw any conclusions relating to comparative analysis of the Mastergraft 1 product compared with the collagen-based scaffolds used in this study. Second, while four animals per group in this study allowed statistical significance between certain groups, the goal of the study was constructed to identify if application of the chosen treatment groups would show a large and beneficial improvement compared with the gold standard of autogenous bone graft. Consequently the results of our study suggest that a powered study evaluating the collagen-hydroxyapatite scaffolds compared directly with commercially available Infuse 1 would likely be of interest. Finally, mechanical assessment was not included in the study because manual palpation of the removed bones at the final time indicated qualitatively comparable structural properties and histologic analysis was preferential. Subsequent in vivo evaluations of the collagenhydroxyapatite study should incorporate quantitative mechanical analysis of the de novo tissue.
The collagen-glycosaminoglycan scaffold examined in this study is a modification of the first collagen scaffold for tissue engineering developed by Yannas et al. in the 1980s [41] [42] [43] . Novel techniques developed in our laboratory maintaining the scaffold's pore architecture while increasing collagen content and compressive strength [12, 19, [21] [22] [23] 33] were used for bone regeneration. Radiographic healing was evident on plain radiographs and lCT. Healing was incomplete but clear callus was seen remodeling through the time points. Histologically immature woven bone was present but not fully occupying the defect and no residual scaffold remained by the final 16-week point. The collagen-glycosaminoglycan scaffold has a stiffness of 1.5 kPa and porosity of 99% [22] . This still may be inadequate to maintain its 3-D anatomy in the osteotomy site with pore collapse inhibiting vascular ingrowth. Although healing in the collagen-glycosaminoglycan scaffold group was incomplete, it was still impressive and suggests that these scaffolds may have uses in low load-bearing craniofacial and mandibular bone defects. In the context of this study, the collagen-glycosaminoglycan scaffold represents a sevenfold increase in compressive modulus relative to the original collagen scaffold designed as a skin graft [41] [42] [43] .
The collagen-hydroxyapatite scaffold improved radiologic, histologic, and histomorphometric healing compared with the collagen-glycosaminoglycan scaffold. The key factor for the improved healing observed in the collagenhydroxyapatite group is believed to be the presence of the hydroxyapatite mineral phase in the scaffold. This novel collagen-hydroxyapatite scaffold is composed of collagen and hydroxyapatite, which are the two main constituents of bone, making it biocompatable, osteoconductive, osteoinductive, and bioabsorbable with nontoxic degradation products [11] . It has been reported that the presence of hydroxapatite contributes potent osteogenic properties [4, 37, [45] [46] [47] . There is increasing evidence to suggest that certain phases of hydroxyapatite have intrinsic osteoinductive properties [17, 18, 46] . Whereas the collagenglycosaminoglycan and collagen-hydroxyapatite scaffolds have high levels of porosity and interconnected pore structures, the differences between the two scaffolds (mechanical properties and composition) may account for the different healing responses because the collagenhydroxyapatite scaffolds are significantly stiffer at 4 kPa [11] . Since the rabbit radius is load-bearing and supports 40% of the rabbit's weight during normal weightbearing [34] , it is thought that the stiffer collagen-hydroxyapatite scaffold would have been better able to maintain its 3-D pore structure, thereby facilitating host cell infiltration into the scaffold. Despite the enhanced mechanical stiffness of the collagen-hydroxyapatite scaffold, it still maintains a porosity of 99%. Higher scaffold porosity has been shown to increase cell proliferation levels attributable to improved transport of oxygen and nutrients [15] as a result of Fig. 4 Radiographic healing (mean values) as interpreted by two of the authors (FGL, HMcA) is shown for each of the treatment groups at Time 0 (Day 1 after surgery), 6, 12, and 16 weeks using the histomorphometry scoring system ( Table 2 ). CG = collagen-glycosaminoglycan; CHA = collagen-hydroxyapatite; CG-BMP-2 = collagen-glycosaminoglycan with BMP-2; CHA-BMP-2 = collagen-hydroxyapatite with BMP-2; ABG = autogenous bone graft.
increased vascularity, which results in an increase in bone ingrowth and new bone formation in vivo [27] . As reported previously [19] , collagen-glycosaminoglycan scaffolds may be less resistant to these mechanical forces resulting in some collapse of the pore structure [19] . Histologic analysis showed that the microanatomy of the bone was fully mature in places and with little or no remnant of the implanted scaffold, suggesting that an appropriate rate of scaffold resoption or bone healing had occurred. Whereas rhBMP-2 groups clearly showed the most rapid healing rates, bone quality analysis clearly showed that although rhBMP-2 and autogenous bone graft groups showed a distinct temporal advantage compared with some groups, the collagen-hydroxyapatite group exhibited a greater BV/ TV ratio compared with all other groups, suggesting a greater proosteogenic effect and reduced osteoclastogenic response in vivo compared with the rhBMP-2 groups. Taken together, this suggests that the collagen-hydroxyapatite scaffold may offer comparable healing properties and a viable alternative to the current clinical gold standard without the considerable clinical disadvantages associated with autogenous bone graft.
The use of the collagen-glycosaminoglycan and collagenhydroxyapatite scaffolds to deliver low-dose rhBMP-2 improved healing compared with the scaffolds alone. The highest level of healing was observed in the collagenhydroxyapatite-rhBMP-2 group, and by 16 weeks, the histologic structure of the bone most closely resembled that of unoperated bone. Three of the four collagen-hydroxyapatite-rhBMP-2 specimens healed completely with no radiographic or histologic evidence of prior intervention. The use of recombinant BMPs has had considerable notoriety since its first approved clinical use in 2002 [6, 7, 9, 10, 31, 36, 40] . Most specifically, the use of doses that are supraphysiologic and the inability to control the rapid rate of degradability of the collagen sponge have raised concerns of not just local, but also systemic leakage of the exogenous rhBMP-2 protein Fig. 7 The graph shows the different bone volumes in the defect (expressed as a percentage) after 16 weeks. There was no statistical difference between bone volumes in the collagen-hydroxyapatite (CHA) and collagen-glycosaminoglycan BMP-2 (CG-BMP-2) groups ( * p = 0.80) and CHA and autogenous bone graft (ABG) groups ( *** p = 0.61). The CHA group had significantly higher cortical bone volume than the CG group (p \ 0.001), and the CHA-BMP-2 group had significantly higher cortical bone volume than all other groups ( ** p \ 0.002). [26] . In our study, a dose of 50 lg of rhBMP-2 per scaffold resulted in near complete anatomic healing in the collagenhydroxyapatite-rhBMP-2 treated defects. Infuse 1 is supplied with a collagen sponge and a vial containing 1.5 mg/cc rhBMP-2 [7] , which corresponds to a final concentration of 1500 ng/mm 3 in humans. Using FDA-recommended body surface area normalization guidelines, the dosage administered to the animals in this study corresponds to approximately 150 ng/mm 3 in humans, which is approximately 10% of the clinically relevant dose of rhBMP-2 used in Infuse 1 . We hypothesized that the lower dose we used managed to create excellent healing of the defect owing to advancements made to the existing scaffolds. The hydroxyapatite phase present in the collagen-hydroxyapatite scaffold confers many mechanobiologic advantages; first, hydroxyapatite has intrinsic osteoinductive properties and the micron-sized hydroxyapatite particles in this scaffold, which are homogenously distributed throughout the scaffold using a patented blending process [24] , are readily resorbed by resident marrow progenitor cells [11] . Second, studies with ceramics have shown that the effects of rhBMP-2 are enhanced when ceramics are used through significantly higher retention rates compared with collagen-only carriers [1, 28, 45] . This not only improves clinical outcome, but also alleviates safety concerns with the current practice using supraphysiologic doses of rhBMP-2; lower amounts can be used, and greater retention of the rhBMP-2 protein minimizes tissue extravasation and vascular leakage.
Whereas these results are of importance to the application of rhBMP-2 and also highlight the contribution of the scaffolds, the most significant finding of this study is that the use of the collagen-hydroxyapatite scaffold shows comparable healing to the current gold standard of autogenous bone graft. In addition, it performed comparably to the collagen-glycosaminoglycan-rhBMP-2 group, which is representative of the commercial device in current clinical use but without the cost and safety concerns. This suggests that the scaffold alone may be used as an effective off-theshelf bone graft substitute. A pilot 10-patient clinical trial is currently being planned. Fig. 8 The graph shows the ratio of new cortical bone volume to tissue volume (BV/TV) of new bone tissue formed in the defect after 16 weeks. There was no statistical difference between groups with the exception of the CHA group, which exhibited a significantly higher BV/TV ratio compared with all other groups. CG = collagenglycosaminoglycan; CHA = collagen-hydroxyapatite; CG-BMP-2 = collagen-glycosaminoglycan with BMP-2; CHA-BMP-2 = collagen-hydroxyapatite with BMP-2; ABG = autogenous bone graft.
